The heregulins are a family of ligands with ability to induce phosphorylation of the p185 receptor. Various investigators have reported a variety of responses of mouse and human breast and ovarian cells to this family of ligands including growth stimulation, growth inhibition, apoptosis and induction of dierentiation in cells expressing the HER-2/neu receptor. Some of the disparity in the literature has been attributed to variations in the cell lines studied, ligand dose applied, methodologies utilized or model system evaluated (i.e. in vitro or in vivo). To evaluate the eects of heregulin on normal and malignant human breast and ovarian epithelial cells expressing known levels of the HER-2/ neu receptor, this report presents the use of several dierent assays, performed both in vitro and in vivo, in vitro proliferation assays, direct cell counts, clonogenicity under anchorage-dependent and anchorage-independent conditions, as well as the in vivo eects of heregulin on human cells growing in nude mice to address heregulin activity. Using a total of ®ve dierent biologic assays in nine dierent cell lines, across two dierent epithelia and over a one log heregulin dose range, we obtained results that clearly indicate a growth-stimulatory role for this ligand in human breast and ovarian epithelial cells. We ®nd no evidence that heregulin has any growth-inhibitory eects in human epithelial cells. We also quantitated the amount of each member of the type I receptor tyrosine kinase family (RTK I, i.e. HER-1, HER-2, HER-3 and HER-4) in the cell lines employed and correlated this to their respective heregulin responses. These data demonstrate that HER-2/neu overexpression itself aects the expression of other RTK I members and that cells expressing the highest levels of HER-2/neu have the greatest response to HRG.
Introduction
A wide variety of growth factors bind to plasma membrane receptors found in human cells of diverse origin and serve to regulate cell growth as well as cellular activities other than mitogenesis (Sporn and Roberts, 1988) . A number of these peptide growth factors bind to the extracellular domains of a variety of receptor tyrosine kinases (RTKs), activating various signal transduction pathways (Aaronson, 1991) .
Structural homologies of known oncogenes to some of these growth factors (GFs) or their cognate receptors indicate a potential role of these molecules in abnormal cell growth (Cross and Dexter, 1991) . Alterations in either the structure or expression level of these genes can induce abnormalities in the control of cell proliferation, resulting in their putative pathogenic role in several human malignancies. The product of the HER-2/neu proto-oncogene is a 185 kD monomeric transmembrane tyrosine kinase (p185 HER-2/neu ) with extensive homology to both the epidermal growth factor receptor (EGFR) and the avian erythroblastosis virus oncogene, v-erbB (Coussens et al., 1985; Prigent and Lemoine, 1992) . Expression of the HER-2/neu proto-oncogene has been demonstrated in a number of normal human fetal and adult tissues, including breast and ovarian epithelia (Lemoine et al., 1989; Natali et al., 1990; Press et al., 1990) . Overexpression of the HER-2/neu receptor is found in 25 ± 30% of human breast and ovarian cancers and is associated with a poor prognosis in those patients whose tumors contain the alteration (Slamon et al., 1987 (Slamon et al., , 1989 Press et al., 1993) . Studies directed at attempting to understand the activation and signal transduction pathways of HER-2/ neu have been limited until recently however, due to the lack of well characterized ligands that activate the p185 RTK. In the past few years, several putative ligands for the p185 HER-2/neu receptor have been reported. Candidate ligands have been isolated from macrophages (Tarahovski et al., 1991) , bovine kidney (Huang and Huang, 1992) , conditioned medium from transformed human T cells (Dobashi et al., 1991) , and rat transformed ®broblasts , as well as human breast cancer cells (Lupu et al., 1992) . None of these molecules however were puri®ed to homogeneity, cloned and/or sequenced, or recombinantly produced, making it dicult to study the speci®c interactions of these putative ligands with the HER-2/neu receptor. Identi®cation, isolation and puri®cation of speci®c activators of p185 HER-2/neu made possible the simultaneous cloning of two homologous ligands; one from human breast cancer cells, heregulin (Holmes et al., 1992) , and the other from rastransformed rat ®broblasts, neu dierentiation factor Wen et al., 1992) . Despite the dierent cell source of heregulin (HRG) and neu dierentiation factor (NDF), the proteins encoded by these genes are identical at the amino acid level. The families of both HRG and NDF consist of a, b and g isoforms (Holmes et al., 1992; Wen et al., 1992; Schaefer et al., 1997) , with a total of 15 members described to date (Marchionni et al., 1993) . Additional data indicate that both proteins induce phosphorylation of p185 HER-2/neu after binding to receptor heterodimers which include HER-2/neu . Heregulin can directly bind p180 and p180 homodimers at low anity, however, resultant phosphorylation only occurs with p180 HER-4 (Plowman et al., 1993; Carraway et al., 1994; Kita et al., 1994) , while HER-2/HER-3 heterodimers constitute a high anity receptor . In addition, formation of HER-2/HER-4 receptor heterodimers which can bind heregulin have been described (Karunagaran et al., 1996) . These as well as other results, including downregulation of binding of EGF to EGFR by heregulin/NDF , suggest that ligand binding can induce a series of complex interactions, resulting from heterodimerization and/or transphosphorylation of speci®c members of the RTK I family by other members of the group. The recent cloning of two new heregulin genes, neuregulin-2 (Carraway III et al., 1997; Chang et al., 1997) and neuregulin-3 (Zhang et al, 1997) , that have dierent RTK I speci®cities, adds further complexity to this ligand-receptor system. The mechanism of type I receptor homo or heterodimerization resulting from HRG binding in human epithelial as well as neural cells is currently the subject of intense investigation. There is an evolving consensus indicating that the HER-2/neu receptor may play a critical role in heregulin-induced RTK I signal transduction (Carraway III et al., 1995; Pinkas-Kramarski et al., 1996; Lewis et al., 1996) . The related biologic activities of HRG and HER-2 are supported by experiments in which these genes were either knocked out and/or mutated in mice, resulting in similar embryonic heart malformation and defects in the development of the neural system, causing embryonic death at day 11 (Meyer and Birchmeier, 1995; Lee et al., 1995) . In addition, studies aimed at testing the eect of HRG on mammary gland development in vivo, mouse mammary epithelial cells cultured in matrigel, as well as mammary carcinoma tissue in explant culture, demonstrate response to addition of HRG by forming alveolar structures and this morphogenic eect is dependent on HER-2 activation of the MAPK kinase signaling pathway (Niemann et al., 1998) .
Heregulin/NDF signaling has been associated with a number of diverse and at times seemingly contradictory biological activities. Heregulin has been reported to have a growth stimulatory eect on the HER-2/neu overexpressing breast cancer cell line SK-BR-3 (Holmes et al., 1992) , as well as on HC11 mammary epithelial cells (Marte et al., 1995) , mouse ®broblasts transfected with HER-2/neu and HER-3 (Carraway III et al., 1995) and 32D murine hematopoietic cells transfected with dierent RTK I combinations (Pinkas-Kramarski et al., 1996) . Conversely, NDF has been reported as a growth inhibitory and dierentiation-promoting factor in MDA-MB-453 and AU-565 mammary carcinoma cells Bacus et al., 1993) , as well as an inducer of apoptosis of breast epithelial cells (Daly et al., 1997) . In addition, the in vivo role of heregulins as growth-stimulatory factors (GFs) is further suggested by reports of the cloning of genes encoding GFs with almost complete identity to HRG/NDF. These two molecules, acetylcholine receptor-inducing activity or ARIA Falls et al., 1993) , and glial growth factor or GGF (Marchionni et al., 1993) , activate phosphorylation of p185 HER-2/neu and promote mitogenesis in cells of the peripheral nervous system. More recent data shows that GGF rescues peripheral nervous system cells from various apoptosis-induced conditions (Kopp et al., 1997; Raabe et al., 1997) .
The putative pathogenic role of the HER-2/neu receptor in at least two major human malignancies (breast and ovarian cancer), and the controversy in the literature regarding the biologic eects of HRG/NDF on cells expressing p185 HER-2/neu , make further understanding of this receptor-ligand system important. -7 H2  MDA-MB-231 NEO  MDA-MB-231 H2  MDA-MB-435 NEO  MDA-MB-435 H2  SK-BR-3   1140000  68100  36000+207  29000+265  4977+193  BDL  201000+1125  76000+995  BDL  BDL  40200+157   5260+1570  210000  4450+125  455000+125  15100+73  1398945+4394  8090+909  115000+126  925+14  28100+371  1957800+1860   283+54  616  354+119  314+105  24600+797  150000+249  1410+135  655+63  7568+25  11500+392  12700+135   141+103  71  BDL  BDL  360+15  296+32  BDL  BDL  BDL  BDL  201+68  Ovarian  2008 PAR  2008 H2  C13 NEO  C13 H2  CaOv3 NEO  CaOv3 H2   109000+150  202000+36  52500+51  85100+102  746+58  BDL   2460+337  104000+339  1260+26  9100+138  5551+232  104567+9999   1020+23  769+63  654+34  653+30  5056+285  4863+1500   300+95  115+16  195+48  175+52  68+4  115+3  Detection limit  606  425  59  40 Receptor levels for all four members of the RTKI family in all the cell lines used were quantitated using a modi®ed ELISA technique. Results re¯ect three independent quantitations, each performed in triplicate and represent the average number of receptors per cell, plus or minus the standard deviation. BDL: below detection limit Figure 1 Eects of HRG on the proliferation of human breast and ovarian epithelial cells. Cells were seeded (10 3 total cells) in 6 well plates using 16RPMI, containing 1% FBS as growth medium (5610 3 total cells for the SKBR-3 cell line). After 24 h of growth at 378C, cells were treated as indicated. Cell numbers were determined after 10 days using a hemocytometer. Cell lines in (a and c) represent normal, immortalized and malignant human breast and ovarian cells which contain a single-copy of HER-2/neu and express normal levels of the receptor. (b and d) illustrate the results obtained for human breast and ovarian cells containing multiple copies of HER-2/neu and overexpressing the receptor. Treatments included excipient control ( ), HRG at 1 nM ( ), or at 10 nM ( ). Standard deviations are represented by bars at top of columns. Asterisks denote statistically signi®cant P values (50.01), when HRG and respective control treatment were compared sensitivity of this ELISA was validated both by comparison with speci®c receptor content as determined by Scatchard analysis in a number of the cell lines (data not shown) as well as by quantitative comparison of the HER-2/neu expression levels in SK-BR-3 and MCF-7 cells. HER-2/neu expression levels have previously been shown to be 128 times higher in SK-BR-3 compared to MCF-7 cells by RNA analysis (Kraus et al., 1987; Paik et al., 1991) . The ELISA data from the current study demonstrates a 129-fold increase in protein content when comparing these two cell lines which is almost identical to the published results and validating the ELISA results. HER-2/neu transfection results in cell lines with 10 ± 100 times more HER-2 receptors/cell compared to matched nonoverexpressing control cells (Table 1 ). This level of overexpression does not exceed the HER-2 level found in the SK-BR-3 cell line which is a natural, nonengineered, overexpressor of HER-2/neu. These transfection studies reveal that the number of receptors/cell for some RTK I members are altered by changes in HER-2/neu expression. Speci®cally, HER-1 (EGFR) expression is decreased and HER-3 expression is increased in 3 of 5 human breast epithelial cells engineered to overexpress HER-2, while human ovarian epithelial cells tended to show the opposite pattern (Table 1 ). In addition, the number of HER-4 receptors/cell is considerably lower than those of the other RTK I receptors (Table 1 ). This result is not due to limitations in the sensitivity of the assay which can detect as little as 40 molecules/cell, but rather to the known low expression levels of HER-4 in breast cells (Pinkas-Kramarski et al., 1996) .
Cell proliferation assays
After quantitation of the RTK I receptor levels in the human cell lines under study, growth assays were performed. Results from growth assays based on cell counts after long-term exposure to HRG in normal, immortalized and malignant human breast as well as malignant human ovarian epithelial cells are summarized in Figure 1a Eects of heregulin on anchorage-dependent and independent growth of human breast and ovarian epithelial cells Two dierent approaches were used to investigate the eects of HRG on anchorage-dependent and anchorage-independent growth in the same panel of human breast and ovarian cell lines. Clonogenic assays evaluate the anchorage-dependent capacity of cells to establish and form colonies when plated at low densities on plastic, while soft agar assays measure the anchorage-independent growth of cells in a semisolid medium. The clonogenic eect of HRG on human breast and ovarian cells which do not overexpress the HER-2 receptor was variable (Figure 2a,c) , however a statistically signi®cant growth-stimulatory dose-response was again consistently observed when testing HER-2/neu overexpressing breast and ovarian cell lines (Figure 2b,d ). Interestingly, cell lines exhibiting no response to HRG treatment in the in vitro cell growth assays (Figure 1) i.e., MDA-MB-231 Eect of HRG on tumor formation in nude mice. Breast and ovarian cells expressing normal levels of HER-2 (a, c, e, g and i) or overexpressing HER-2/neu (b, d, f, h and j) were injected into nude mice. Estrogen support was provided by subcutaneous implantation of estrogen pellets 24 h prior to cell inoculation. Estrogen-de®cient (ovariectomized) nude mice with no estrogen supplement were used (i and j). HRG (*) or the excipient control (&) were administered every other day starting 5 ± 7 days after cells were implanted. Tumor volumes were measured at the indicated times. Arrows indicate the time at which HRG injection was stopped. Cell lines are as labeled in ®gure and OV 2008, were responsive to treatment with HRG at both 1 and 10 nM in the anchorage-dependent assays (Figure 2a,c) . Heregulin treatment results in formation of large diameter colonies compared to those of the normal human breast cell line HMEC, which generated very small colonies containing fewer cells (compare Figures 1a and 2a) . This observation again underscores the point that the type of assay used can eect the result and may explain some of the variation in the published literature. Overall, the data from these studies indicate a profound stimulatory eect of HRG on the anchorage-dependent growth in all HER-2 overexpressing cells as well as some of the non-overexpressing cells.
Anchorage-independent growth assays conducted in semi-solid medium also demonstrated the capacity of HRG to promote in vitro colony growth in soft agar ( Figure 3 ). All human breast and ovarian cell lines (both non-transformed and malignant) which overexpress HER-2/neu again demonstrate a dose-dependent growth-stimulatory eect when tested in the semisolid medium (Figure 3a ± d) . The only exception to this observation was the normal human breast epithelial cell line HMEC, which does not form colonies in semi-solid medium even with HER-2/neu overexpression (data not shown). Heregulin at a dose of 10 nM resulted in a decrease in the amount of colonies formed by MCF-7/H2 cells when compared to the 1 nM HRG dose. This does not however imply a growth inhibitory eect, since the number of colonies at the 10 nM dose was still greater than that obtained in the respective control wells. Regression analysis of response to HRG (HRG/XC) and RTK I receptor content again shows that the degree of responsiveness to HRG in both anchorage ± dependent as well as anchorage ± independent assays is linearly correlated with expression of the HER-2/neu receptor, with P values of 0.00007 and 0.00002 for the 1 and 10 nM doses respectively.
[ 3 H]thymidine incorporation assays were also performed and demonstrated HRG-induced increased counts (data not shown). The data from this panel of nine separate human breast and ovarian cell lines using two dierent doses of HRG and four dierent and independent in vitro cell growth assays, indicate a consistent and generic growth-stimulatory, rather than a growth-inhibitory eect for this ligand. These results support the initial data indicating a mitogenic activity of both HRG-a and HRG-b1 on cell lines overexpressing HER-2/neu (Holmes et al., 1992) . Moreover, these results agree with the bulk of published literature showing that b forms of HRG are mitogenic (Lewis et al., 1996; Lu et al., 1995) . In the present study we ®nd no indication of a growth-inhibitory and/or differentiation eect, as previously reported by other investigators working with NDF/HRG Bacus et al., 1996) .
In vivo tumorigenesis
The above results are restricted to the eects of HRG/ NDF on human breast and ovarian cancer cells in in vitro assays. Because in vitro response data may be more related to ex vivo growth conditions than generic biologic growth responses we decided to evaluate HRG eects in vivo. Tumorigenesis in nude mice is a widely accepted method of evaluating compounds for growth stimulation or inhibition of cells growing in vivo (Freshney, 1985) . Results were obtained for the tumorigenic activity of HRG, as determined by implanting breast and ovarian cells subcutaneously into both non-estrogen primed and estrogen primed female nude mice and treating the animals with HRG (Figure 4) . Cell lines were initially implanted into nude (Figure 4i,j) . After establishment of tumors (5 ± 7 days), animals were treated with rHRG-b1 or diluent control by subcutaneous injection. Comparison of in vivo growth of three dierent human breast and ovarian cell lines expressing normal levels of HER-2/neu (Figure 4a , c and e) as well as these same cells engineered to overexpress the gene (Figure 4b,d,f) demonstrates an increase in in vivo tumor formation induced by HRG treatment. A signi®cant dierence (P=0.0001) was obtained for the growth of the immortalized breast cell line HBL-100 treated with HRG ( Figure 4a ) and this dierence (P=0.0006) was again observed in transformed, HER-2/neu overexpressing HBL-100 cells (Figure 4b ). Tumors in mice implanted with MCF-7 parental cells and treated with rHRG-b1 were 1.6 ± 2 times larger at day 15 (P=0.008) and 3 times larger at day 32 (P50.01) when compared to mice injected with excipient control (Figure 4c ). In addition MCF-7 cells engineered to overexpress HER-2/neu, formed tumors in both HRG-treated and the excipient control-treated groups, however tumor size in the heregulin treated group was again 1.6 times greater (P50.002) than in the control group by day 32 ( Figure  4d ). Larger tumors were also observed in HRG-treated mice implanted with non-overexpressing (P=0.02) as well as overexpressing (P=0.03) ovarian cancer cell line CaOv3 (Figure 4e,f respectively) .
We also performed tumorigenicity assays for the estrogen-dependent MCF-7 non-overexpressing as well as the transfected HER-2 overexpressing matched cells in ovariectomized (estrogen-de®cient) animals. These data demonstrate a signi®cant (P=0.0001 and P50.01 respectively) growth stimulatory eect of HRG on tumor formation for both cell lines in the absence of estrogen (Figure 4i and j) . The data also demonstrate that MCF-7 cells overexpressing HER-2/neu are estrogen independent with respect to growth, but still respond to HRG supplementation (Figure 4j ). The growth-stimulatory eect of HRG on cell lines growing in vivo was further evidenced when ligand injection was stopped. To determine the eects of endogenous production of HRG by implanted cells as well as the eects of natural (non-engineered) HER-2 overexpression on response to exogenous HRG, we evaluated the MDA-MB-231 and SK-BR-3 cells respectively ( Figure  4g,h) . The heregulin-producing malignant breast cell line MDA-MB-231 did not signi®cantly form larger (P=0.07) tumors in mice treated with HRG when compared to control-treated animals (Figure 4g ). Conversely, SK-BR-3 cells which overexpress HER-2/ neu but which do not produce endogenous HRG or grow in nude mice will form tumors with HRG treatment (P=0.0001) (Figure 4h ).
Quantitation of endogenous heregulin production by human breast and ovarian epithelial cells
Given the in vivo results obtained with the MDA-231 cells, it is possible that endogenous HRG production could eect response to exogenous HRG (Figures 1a  and 4g , MDA-MB-231 cells). As a result we wished to determine if any of the other cells analysed in this study produced the ligand. All of the cell lines studied were analysed for HRG synthesis using a quantitative PCR technique called Taqman (Gibson et al., 1996; Heid et al., 1996) (Figure 5 ). The normal and immortalized human breast cell lines, HMEC and HBL-100, as well as their HER-2 transfected counterparts produce HRG. Conversely among the malignant breast cell lines, only MDA-MB-231 cells synthesize the ligand. Demonstration of HRG production by the MDA-MB-231 cells is consistent with previous data (Holmes et al., 1992) . MCF-7, MDA-MB-435 and SK-BR-3 cells make no detectable HRG. An interesting phenomenon occurs for the 2008 ovarian cancer cells and their platinum-resistant derivatives, C13 ( Figure  5 ). Heregulin expression is consistently increased in these cells after HER-2 transfection and overexpression. The opposite phenomenom was observed for the normal and immortalized breast cell lines HMEC and HBL-100 respectively, where a reduction of HRG expression is observed with HER-2 overexpression. These results were con®rmed by Northern blot analysis (data not shown). The malignant ovarian human cell line CaOv3 and its HER-2 overexpressing transfectant however do not make the ligand.
Discussion
HER-2/neu is a member of the type I receptor tyrosine kinase family (RTK I) of epithelial growth factor receptors. Transfection and overexpression of this gene confers a growth advantage and induces transformation of a number of non human, mammalian cells in vitro (Hudziak et al., 1988; Chazin et al., 1992) . In addition, HER-2 overexpression resulting from gene ampli®cation occurs in 25 ± 30% of human breast and ovarian cancers and this overexpression is associated with poor prognosis in those patients whose cancers contain it (Slamon et al., 1987 (Slamon et al., , 1989 Press et al., 1993) . The potential pathogenic role of overexpression of this growth factor receptor in two major human malignancies has made understanding the biologic eects of its activation the subject of intense investigation. Many growth factors are capable of displaying mitogenic, dierentiation or growth inhibitory eects on target cells (Sporn and Roberts, 1988) . Pleiotropic response to peptide growth factors assayed under dierent conditions is a well documented phenomenom (Sporn and Roberts, 1988) . The objective of this study was to evaluate biologic eects of heregulin on human breast and ovarian epithelial cells expressing de®ned levels of the HER-2/neu receptor, spanning the spectrum from normal levels to the overexpressed levels found in cells with HER-2/neu ampli®cation. The isolation, purification and cloning of heregulin (Holmes et al., 1992) , an activator of RTK Is including HER-2/neu, makes investigation of the biologic eects of this ligand possible. In this study a variety of growth assays were used to evaluate a large number of human breast and ovarian epithelial cells growing both in vitro and in vivo across a one log concentration of HRG. This approach was undertaken to circumvent the possibility that biologic eects which are unique to a speci®c cell line, method of analysis or dose level, might lead to incorrect conclusions as to the generic eects of this ligand. The results obtained using this approach provide a consistent and reproducible picture of HRG response in human breast and ovarian epithelial cells. The data demonstrate a varying growth response to HRG in cell lines containing a single copy of the HER-2/neu gene and expressing normal amounts of the gene product. The immortalized breast epithelial cell line, HBL-100, as well as malignant breast cell lines MDA-MB-231 and MCF-7 all contain a single copy of HER-2/neu gene and express normal levels of the protein (Press et al., 1993) . The non-ampli®ed, nonoverexpressing MDA-MB-231 and HBL-100 cells do not respond to HRG treatment, while MCF-7 cells exibit a growth-stimulatory response. Examination of RTK I levels in these cell lines demonstrates that the MCF-7 cells express greater levels of HER-2 (1.9 ± 3.4-fold) and HER-3 (17 ± 69-fold) than those found in HBL-100 and MDA-MB-231 cells. This phenomenon could account for the dierences in growth response, since HER-2/HER-3 heterodimers are known to be important in the signaling response associated with HRG (Riese et al., 1995; Beerli et al., 1995) . This is further supported by the lack of responsiveness of the normal breast epithelial cell line HMEC, which contains relatively low levels of HER-3 receptor. An alternative explanation for this dierence could relate to the fact that both the MDA-MB-231 and HBL-100 cell lines produce HRG endogenously, while MCF-7 cells do not. The endogenous production of this ligand may stimulate cell growth via an autocrine mechanism (Schaefer et al., 1997) , lessening the eects of exogenously added HRG. With the single exception of HMEC cells, transfection of HER-2/neu and its concomitant overexpression results in a growthstimulatory response to HRG in the in vitro growth proliferation assay in all breast and ovarian cell lines examined, regardless of endogenous HRG expression. Additionally, in the current study we demonstrate that treatment with HRG results in further increased growth of cells that overexpress HER-2/neu.
Results of the anchorage-dependent assays also demonstrated a correlation between overexpression of the HER-2/neu receptor and a HRG-induced growth stimulatory and clonogenic responses in both normal and malignant breast epithelial cells as well as ovarian cancer cells. It is interesting to note that the malignant breast cell line MDA-MB-231, which do not show a response to HRG in the cell proliferation assay, display a signi®cant concentration-dependent increase in colony formation in the anchorage-dependent growth assay underscoring the need to evaluate biological responses by more than one assay. The linear correlation coecients obtained between anchoragedependent growth and HER-2 receptor number again demonstrates a relationship between HER-2 expression and response to heregulin and further supports the concept that HER-2/neu is an important mediator of HRG-induced clonogenic growth activity in human breast and ovarian cells. The results also support a role for HRG as a survival factor as reported by investigators working with neural derived cells (Koop et al., 1997; Raabe et al., 1997) , since cells plated at low density and in low serum, i.e. clonogenic conditions, not only survived but were growthstimulated by the ligand. Finally, in experiments aimed at detecting the possible eects of HRG on apoptosis, MCF-7 parental, MCF-7 RV/H2 and SK-BR-3 cells were stained for Anexin V after 3, 5 and 10 days of incubation (data not shown). These studies failed to con®rm induction of apoptosis by HRG in malignant breast cells as reported by others (Daly et al., 1997) . Results from soft agar assays further con®rm the stimulatory eects of HRG on anchorage-independent growth. Immortalized, nontransformed as well as malignant breast, and ovarian epithelial cell lines overexpressing HER-2/neu demonstrate a marked increase in soft agar growth in response to HRG exposure.
Tumorigenicity of both parental and HER-2/neu transfected cells in nude mice treated with HRG was consistently higher when compared to the growth observed in untreated mice. Only the MDA-MB-231 breast cancer cells were unaected by treatment with HRG, perhaps due to endogenous HRG production by this cell line. In vivo HRG treatment of ovariectomized mice implanted with the estrogen-dependent MCF-7 parental cells yielded interesting results. As expected no tumor growth was observed in control mice, however tumors did form with HRG treatment. These results suggest that HRG is able to overcome at least some of the estrogen-dependency of MCF-7 cells in vivo and further substantiate the role of this ligand as a growthstimulatory factor. Previous studies from our laboratory have shown direct interactions between the estrogen receptor and p185
HER-2/neu , suggesting a mechanism for estrogen-independence in HER-2/neu overexpressing breast cancer cells (Pietras et al., 1995) .
Previously published studies have reported a variety of dierent and sometimes opposite eects of HRG/ NDF on human breast epithelial cells. Heregulin/NDF has been reported to induce growth inhibition and/or cell dierentiation (Lupu et al., 1992; Peles et al., 1992; Bacus et al., 1996) as well as apoptosis (Daly et al., 1997) in some cell lines. Conversely, growth stimulation by HRG has been reported in other cells (Holmes et al., 1992; Marchionni et al., 1993; Carraway III et al., 1995; Levi et al., 1995; Marikovsky et al., 1995; PinkasKramarski et al., 1996; Marte et al., 1995; Lewis et al., 1996) . In general these reports have evaluated a limited number of cell lines and/or used a speci®c in vitro assay as well as a ®xed concentration of HRG/NDF. Some reports in which treatment of cells with NDF resulted in growth inhibition or cell dierentiation used the MDA-MB-453 and AU-565 cell lines (Bacus et al., 1993; Daly et al., 1997) . We did not evaluate these two cell lines in this study; however, other investigators have previously reported growth stimulation of MDA-MB-453 cells when treated with the same doses of HRG in 1% FBS (Lewis et al., 1996) . Moreover, the AU-565 cells are derived from the same patient as SK-BR-3 cells, sharing a common origin (Bacus et al., 1993) . Similarly use of in vitro assays alone to characterize biological responses to a ligand can be misleading. An example of this is the fact that the initial published literature on the eects of high dose EGF demonstrated a growth inhibitory response, however subsequent studies demonstrated EGF to be clearly growth-stimulatory in vivo (reviewed in Carpenter and Cohen, 1990; Khazaie et al., 1993) . Further evidence supporting the growth stimulatory activities of HRG/NDF on breast cancer cells is found in two recent reports in which the eects of NDF were studied in two dierent in vivo models. In the ®rst, NDF expression induced formation of adenocarcinomas (Krane and Leder, 1996) . In the second, transfection of the human breast cancer cell line MDA-MB-435 with either scatter factor (HGF) or HRG/NDF increased tumor size at the primary site and induced metastasis of transfected cells to the lungs (Meiners et al., 1998) .
Binding of heregulin to two dierent members of the RTK I family, speci®cally HER-3 , and HER-4 (Plowman et al., 1993) , as well as the documented interactions between these receptors and EGFR (Prigent and Lemoine, 1992; Karunagaran et al., 1995 Karunagaran et al., , 1996 Pinkas-Kramarski et al., 1996; Riese et al., 1995; Spivak-Kroizman et al., 1992; Qian et al., 1994; Alimandi et al., 1997) , suggests that complex combinations of receptor-ligand interactions are occurring in human cells expressing these receptors. Additionally, binding of EGF to HER-2/HER-3 heterodimers occurs (Alimandi et al., 1997) , indicating that competition between HRG and EGF for binding to this receptor combination might occur in vivo. The current results indicate that expression of all four RTK I receptors varies signi®cantly from cell to cell and that HER-2 receptor number can signi®cantly eect expression of the other RTK I members. This report also indicates that biological responses to heregulin both in vitro and in vivo are directly correlated with HER-2/neu expression levels. This con®rms results from other investigators indicating that heregulin signaling through HER-3 and HER-4 may be dependent on HER-2/neu expression levels in breast (Riese et al., 1995; Beerli et al., 1995) as well as prostate cells (Leung et al., 1997; Grasso et al., 1997) . The observed variability for the expression of the dierent RTK type I, in particular the changes in HER-3 number post HER-2 transfection, most likely have an impact on the extent of the eect of HRG. This could explain the observed range in growth stimulatory responses resulting from treatment with heregulin. Results in the current study however, do not support a signi®cant role for HER-4 as an important molecule in the growth stimulatory HRG-induced eects in human breast and ovarian epithelial cells.
There are published reports of dierentiation induced by NDF in breast cancer cells growing in high fetal bovine serum (FBS) concentrations . These reports, however, studied changes in expression of casein and milk fat globulin which are markers of mammary cell maturation rather than tumor cell dierentiation (Stampfer and Yaswen, 1999) . It should be noted that normal breast epithelial cells show a high degree of phenotypic plasticity in monolayer and express many features of malignant cells in vivo (Barcellos-Hoft et al., 1989; Petersen et al., 1992) . In addition, the use of conditioned medium and FBS introduces variables due to the presence of other growth regulatory activities in serum which make it dicult to evaluate the eects of a speci®c growth factor, i.e. HRG/NDF, on cell growth. Indeed previous reports have demonstrated that study of the behavior of transformed cell lines growing in monolayer cultures may be less useful in assessing the activity of a speci®c growth factor on cell dierentiation (Petersen et al., 1992) . All assays in the current study were performed using 1% FBS in the culture medium. Lowering the concentration of serum in the culture medium should diminish the eects of other serum GFs which activity could mask, or alter HRG eects on the cell lines (Lewis et al., 1996) . A potential diculty in lowering serum concentration to 1% is that itself can inhibit cell growth. This did not occur with the cell lines used in this study (Figures 1 ± 3 , see Lewis et al., 1996) . Published reports on the eects HRG/NDF activity have also been confounded by the use of dierent recombinant forms of the ligand that span overlapping, but not identical regions of the molecule and/or by the use of dierent isoforms of HRG which are reported to promote activation of dierent receptor combinations (Pinkas-Kramarski et al., 1996; Weiû et al., 1997) .
Given the putative role of HER-2/neu in the pathogenesis of human breast and ovarian cancer, characterization of the nature and biologic eects of ligands which either directly or indirectly interact with this receptor are of potential signi®cance. The current study demonstrates that a number of human breast and ovarian cells expressing normal levels of HER-2 are growth-stimulated by HRG and that when these same cells overexpress the receptor, growth stimulation is a uniform response. A more complete understanding of the growth activity signals generated through HER-2/neu as well as other RTK I family members could have important therapeutic implications in human breast and ovarian cancers.
Materials and methods

Cell lines
Normal human mammary epithelial cells (HMEC) were purchased from Clonetics (San Diego, CA, USA) and grown as directed by the supplier. Immortalized human breast cells (HBL-100), and the breast carcinoma cell lines MCF-7, MDA-MB-231, MDA-MB-435, SK-BR-3 as well as the ovarian malignant cell line CaOV3 were obtained from the ATCC (American type culture collection). The ovarian cell line 2008 and its platinum-resistant subclone C13 were kindly provided by Dr Steven Howell (University of California, San Diego, USA). All cell lines with the exception of HMEC were routinely maintained in RPMI medium (Gibco), containing 10% heat inactivated fetal bovine serum (FBS), penicillin and streptomycin. Non-tranfected, parental cell lines, are designated by the sux PAR. HER-2/neu overexpressing cell lines designated by the sux /H2, and the mock transfected cell lines (/NEO) were generated by multiple infections of cells with a replication defective retroviral vector containing a full-length human HER-2 cDNA with a neomycin resistance gene and control cells were transfected with the vector containing the neomycin gene alone as described (Chazin et al., 1992) .
Cell proliferation assays
Cells were plated in six well plates (four plates/cell line) at the desired cell density (1000 cells/well or as otherwise indicated) in RPMI containing 1% FBS. After incubation at 378C with 5% CO 2 , for 24 h, the 7 kDa rHRG ± b1 ligand, or control solution (0.1% Tri¯uoroacetic acid, 30% CH 3 CN) were added at two dierent doses to the plates (1 and 10 nM ®nal concentration in a total volume of 3 ml). Cells were then incubated at 378C with 5% CO 2 and after 10 days of growth, half of the plate (three wells) was used for direct cell counts by trypan blue exclusion, and half was used for colony counts (see clonogenic assay below). All in vitro assays were performed in triplicate two to three times. Results obtained were analysed using the Mann Whitney U-non-parametric statistical test (Stat View 4.5, Abacus concepts; Berkeley, CA, USA).
Anchorage dependent and independent growth
Clonogenic assays were performed as described above on plastic to measure anchorage-dependent ability of cells to form colonies when plated at low densities (Paraskeva et al., 1990) . The total number of colonies/well/plate was determined by staining with hematoxylin using standard cytochemical techniques. Quantitation of colonies in soft agar was used to measure anchorage-independent growth. Using a 0.3 ml bottom layer of 0.4% agar (Collaborative Research) in 1% FBS RPMI formed in the eight central wells of a 24 well plastic dish. After solidi®cation of the bottom layer, a top layer containing a total of 2000 cells and the desired concentrations of either diluent control or 7 kD rHRG-b1 (1 and 10 nM) in 0.3 ml of 0.2% agar in 16RPMI was layered on top. Colonies were stained with 0.2 mg/ml tetrazolium violet (Sigma, St Louis, MO USA) in PBS after 2 ± 4 weeks and quantitated by direct observation with an inverted microscope (Diaphot, Nikon, Japan).
Tumorigenesis
Tumor formation by cells expressing low and high levels of HER-2/neu were determined after implantation of cells in female nude mice (n=8 per treatment group) either with or without estrogen supplementation (1.7 mg pellet subcutaneously). Recombinant heregulin-b1 was injected at a dose of 2 mg/kg subcutaneously every other day. Tumor size was measured in three dimensions with micrometer calipers. Tumor measurements collected at each time point were compared using a two way statistical analysis of variance throughout the course of the experiment (unless otherwise indicated) using Super ANOVA and StatView 4.5 (Abacus concepts; Berkeley, CA, USA) programs.
Preparation of cell lysates for receptor quantitation
Cells were grown to approximately 90% con¯uence and harvested using PBS with 2 mM EDTA then counted and stored as frozen cell pellets. Lysates were prepared by thawing and resuspending the cells in 25 mM Tris, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1.0% v/v Triton X-100, 1.0% w/v CHAPS, 10% v/v glycerol (lysis buer) with 0.2 mM PMSF, 10 KIU/ml aprotinin, 10 mM leupeptin and 16 mM bestatin.
RTK I receptor quantitation
RTK I receptor (HER 1, HER-2, HER-3 and HER-4) expression levels for each cell line used in this study were determined using a receptor speci®c enzyme linked immunosorbent assays (ELISA). The assays were con®gured in a sandwich format in 96-well plates (Immulon 4, Dynatech) coated with receptor speci®c monoclonal antibodies by incubating them with puri®ed speci®c anti-RTK I antibodies, diluted to 1.0 mg/ml in 50 mM carbonate, pH=9.6, overnight at 48C. Monoclonal antibodies 13A9, 2H11, 2F9, and 1E3, (Genentech, Inc. South San Francisco, CA, USA) were used for the EGFR, HER-2, HER-3, and HER-4 assays, respectively. These antibodies recognize speci®c epitopes within the extracellular domains of their corresponding receptors. The following day ELISA plates were blocked with 2.0% w/v BSA in 25 mM Tris, pH=7.5, 150 mM NaCl, 0.02% v/v Tween 20 (TBST) for 1 h at room temperature. Cell lysates were added to the MAb coated plates and incubated for at least 1 h at room temperature. The plates were then washed with TBST and incubated with polyclonal detection antibodies. Rabbit polyclonal antibodies (Santa Cruz) speci®c for cytoplasmic domain epitopes were used for the HER-1, HER-3 and HER-4 assays. A guinea pig polyclonal antibody (Genentech) raised against the extracellular domain of HER-2 was used for the HER-2 assay. After 1 h, plates were washed with TBST and incubated with anti-primary-biotinylated, then with streptavidin-HRP, followed for an additional incubation with a streptavidinperoxidase conjugate (Calbiochem). Following a ®nal wash with TBST the plates were developed using a pre-formulated o-phenylenediamine substrate tablet (Sigma). A puri®ed recombinant fragment of HER-2, corresponding to the extracellular domain of the full-length receptor, was used to standardize the HER-2 ELISA. Serial dilutions of cell lysates containing known receptor concentrations were used to generate standard curves for the HER-1, HER-3, and HER-4 ELISA's. K562 transfectants were used for the HER-3 and HER-4 standard lysates, and MDA 468 cells were used for the HER-1 standard lysate. Validation of the ELISA assay was performed by determining receptor content using Scatchard analysis of receptor content (Munson and Rodbard, 1980) in competitive ligand binding experiments (Holmes et al., 1992) . The limit of sensitivity for each assay was set at 10% of the basal signal for the standard lysate curves and the detection limits expressed in molecules/cell for each receptor were 606, 425, 59 and 40 for HER-1, HER-2, HER-3 and HER-4 respectively. Regression analyses were performed using StatView 4.5 (Abacus concepts; Berkeley, CA, USA).
Real time quantitative PCR (TaqMan)
Heregulin mRNA was quantitated in each cell line using RT ± PCR or TaqMan as previously described (Gibson et al., 1996; Heid et al., 1996) . The sequence of the primer/probe set, speci®c to the EGF domain of HRG, used in this analysis are shown below: F, 5'-TGTGCGGAGAAGGAGAA-AACTTTCT-3'; R, 5'-GTTGGCACTTGCACAAGTATC-TCG-3'; P, 5'-FAM-CTTACAAGCCGCATCGATTTTGT-C-TAMRA-p-3'; where F and R are the forward and reverse primers respectively, and P is the¯ourescent labeled probe. Ribosomal protein L19 (RPL19) was used as the housekeeping gene. Primer/probe sets for RPL19 are: F, 5'-ATGTATCACAGCCTGTACCTG-3'; R, 5'-TTCTTGGT-CTCTTCCTCCTTG-3'; P, 5'-FAM-AGGTCTAAGACC-AAGGAAGCACGCAA-TAMRA-p-3'.
TaqMan analysis was performed in a standard 96-well plate format using an ABI PRISM 7700 Sequence Detection System instrument and software (PE-Applied Biosystems, Inc). Standard curves were constructed using 0.8 ± 200 ng total RNA isolated from the breast cell line MDA-MB-231 for HRG and 0.3 ± 75 ng for RPL19. Each dilution was run in duplicate. For samples derived from the respective cell lines 100 ng were analysed in triplicate for HRG and RPL19.
